B. Riley likes Actinium, sees a four-bagger

|About: Actinium Pharmaceutica... (ATNM)|By:, SA News Editor

B. Riley FBR is bullish on Actinium Pharmaceuticals (ATNM -2.4%) based on its novel antibody-radioisotope conjugate (ARC) approach to treating blood cancers (BUY/$2.75).

Lead candidate is Phase 3-stage Orphan Drug-tagged Iomab-B used to prepare and condition leukemia patients for bone marrow transplant.

Number two candidate is Actimab-A, in Phase 2 development for acute myeloid leukemia.

Source: Bloomberg

Previously: Actinium's webinar on lead product candidate Iomab-B fails to excite investors; shares down 27% in a week (June 14)

Previously: Actinium advancing mid-stage study of leukemia med Actimab-A; shares ahead 10% premarket (Oct. 4)

Subscribe for full text news in your inbox